What is CJC-1295?
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone. Researchers developed it to investigate whether modifying GHRH could substantially extend its biological activity.
CJC-1295 and growth hormone research
GHRH is a hypothalamic signalling peptide involved in stimulating growth-hormone release from the pituitary gland. A randomised controlled study in healthy adults published in 2006 reported prolonged, dose-dependent elevations in measured GH and IGF-1.
With DAC vs without DAC
The original long-acting CJC-1295 compound contained a Drug Affinity Complex designed to bind to albumin and extend activity. Products described as CJC-1295 without DAC generally refer to a shorter-acting GHRH analogue.
Evidence status
Mechanistic rationale is established and controlled human pharmacodynamic research is available.